论文部分内容阅读
糖尿病黄斑水肿(diabetic macular edema,DME)是发达国家致盲性眼病的重要原因,血管内皮生长因子(vascular endothelial growth factor,VEGF)在DME的发生发展中发挥重要作用,成为DME的重要治疗靶点。近年来的研究结果显示抗VEGF药物的治疗效果优于传统激光或糖皮质激素。本文综述抗VEGF药物最新的研究进展。
Diabetic macular edema (DME) is an important cause of blinding ophthalmopathy in developed countries. Vascular endothelial growth factor (VEGF) plays an important role in the occurrence and development of DME and becomes an important therapeutic target of DME . In recent years, the results of the study show that the anti-VEGF drug treatment is superior to traditional laser or glucocorticoid. This article reviews recent advances in anti-VEGF drugs.